FdaApplication
NDA 205776
Identifiers
- fda_app_no: NDA205776
Properties
| Property | Value |
|---|---|
| applicant_name | MEDEXUS PHARMA INC |
| application_type | NDA |
| approval_date | 2014-07-10 |
Products (10)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RASUVO | METHOTREXATE | 27.5MG/0.55ML (27.5MG/0.55ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 12.5MG/0.25ML (12.5MG/0.25ML) | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 22.5MG/0.45ML (22.5MG/0.45ML) | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 17.5MG/0.35ML (17.5MG/0.35ML) | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 15MG/0.30ML (15MG/0.30ML) | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 20MG/0.4ML (20MG/0.4ML) | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 25MG/0.5ML (25MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 10MG/0.20ML (10MG/0.20ML) | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 7.5MG/0.15ML (7.5MG/0.15ML) | SOLUTION;SUBCUTANEOUS |
| RASUVO | METHOTREXATE | 30MG/0.6ML (30MG/0.6ML) | SOLUTION;SUBCUTANEOUS |
10 products